2024, Number 2
<< Back Next >>
Rev Mex Traspl 2024; 13 (2)
Acute antibody mediated rejection, a challenge for transplant doctors
Fernández-Vivar C, Cano-Cervantes JH, Matías-Carmona M, Coral-Vázquez RM, Canto-Cetina IP
Language: Spanish
References: 37
Page: 77-84
PDF size: 333.58 Kb.
ABSTRACT
The antibody mediated rejection is associated with a reduction in glomerular filtration in about 20% between the first 12 months after the diagnosis, and with an increase in kidney failure. The recipients with rejection have about 50% of risk to lost kidney function allograft compared with those without inmunological event during it evolution, the risk is greatest in acute antibody mediated rejection with vascular component. The gold standard diagnostic method for acute antibody mediated rejection is allograft biopsy. The allograft histology is determined by Banff classification, this classification has had update since its creation in 1990; according to Banff classification 2019, the diagnosis of acute antibody mediated rejection include histology, C4d and ADES. The standard treatment is methylprednisolone, plasmapheresis and immunoglobulin with or without rituximab, there are others additional treatments, but not one have proved to be enough effective.
REFERENCES
Irish W, Nickerson P, Astor BC et al. Change in estimated GFR and risk of allograft failure in patients diagnosed with late active antibody-mediated rejection following kidney transplantation. Transplantation. 2021; 105: 648-659.
Everly MJ, Rebellato LM, Haish CE et al. Incidence and impact of de novo donor-specific alloantibody in primary renal allografts. Transplantation. 2013; 95: 410-417.
Loupy A, Hill GS, Jordan SC. The impact of donor-specific anti-HLA antibodies on late kidney allograft failure. Nat Rev Nephrol. 2012; 17: 348-357.
Sellares J, Freitas DG, Mengel M et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant. 2012; 12: 388-399.
Einecke G, Sis B, Reeve J et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant. 2009; 9: 2520-2531.}
Starzl TE. Personal reflections in transplantation. Surg Clin North Am. 1978; 58: 879-893.
Wiebe C, Gibson IW, Blydt-Hansen TD et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant. 2012; 12: 1157-1167.
Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med. 2003; 349: 2326-2333.
Hart A, Smith JM, Skeans MA et al. OPTN/SRTR 2015 Annual data report: kidney. Am J Transplant. 2017; 17 Suppl 1 (Suppl 1): 21-116.
Saran R, Li Y, Robinson B et al. US renal data system 2014 annual data report: Epidemiology of kidney disease in the United States. Am J Kidney Dis. 2015; 66 suppl 1: S1-306.
McDonald S, Russ G, Campbell S, Chadban S. Kidney transplant rejection in Australia and New Zealand: relationships between rejection and graft outcome. Am J Transplant. 2007; 7 (5): 1201-1208.
Cherukuri A, Mehta R, Sharma A et al. Post- transplant donor specific antibody is associated with poor kidney transplant outcomes only when combined with both T-cell-mediated rejection and non-adherence. Kidney Int. 2019; 96: 202-213.
Yeh H. Applications of transcriptomics in the research of antibody-mediated rejection in kidney transplantation: progress and perspectives. Organogenesis. 2022; 18 (1): 2131357.
Cooper JE. Evaluation and treatment of acute rejection in kidney allografts. Clin J Am Soc Nephrol. 2020; 15 (3): 430-438.
Loupy A, Haas M, Roufosse C et al. The Banff 2019 Kidney Meeting Report (I): updates on and clarification of criteria for T cell- and antibody-mediated rejection. Am J Transplant. 2020; 20 (9): 2318-2331.
Lefaucheur C, Loupy A, Vernerey D et al. Antibody-mediated vascular rejection of kidney allografts: a population-based study. Lancet. 2013; 381 (9863): 313-319.
Pottebaum AA, Venkatachalam K, Liu C et al. Efficacy and safety of tocilizumab in the treatment of acute active antibody-mediated rejection in kidney transplant recipients. Transplant Direct. 2020; 6 (4): e543.
Comai G, Ravaioli M, Baraldi O et al. Treatment of acute antibody-mediated rejection. Contrib Nephrol. 2017; 190: 156-167.
Bohmig GA, Eskandary F, Doberer K, Halloran PF. The therapeutic challenge of late antibody-mediated kidney allograft rejection. Transpl Int. 2019; 32 (8): 775-788.
Roberts DM, Jiang SH. The treatment of acute antibody-mediated rejection in kidney transplant recipients-a systematic review. Transplantation. 2012; 94: 775-783.
Tatar E, Uslu A, Simsek C, Vardar E. Evaluation of late antibody-mediated rejection (C4d-mediated rejection): a single-center experience. Exp Clin Transplant. 2015; 13 Suppl 1: 259-262.
Wan SS, Ying TD, Wyburn K et al. The treatment of antibody-mediated rejection in kidney transplantation. Transplantation. 2018; 102 (4): 557-568.
Tasli Alkan F, Tatar E, Karatas M et al. Response to treatment in kidney transplant recipients with acute antibody-mediated rejection: A follow-up biopsy study. Clin Nephrol. 2020; 93 (2): 85-90.
Yamada C, Ramon DS, Cascalho M et al. Efficacy of plasmapheresis on donor-specific antibody reduction by HLA specificity in post-kidney transplant recipients. Transfusion. 2015; 55 (4): 727-735; quiz 726.
Moreso F, Crespo M, Ruiz JC et al. Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: A multicenter, prospective, randomized, double-blind clinical trial. Am J Transplant. 2018; 18 (4): 927-935.
Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009; 9 Suppl 3: S1-155.
Gaber AO, First MR, Tesi RJ et al. Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation. Transplantation. 1998; 66 (1): 29-37.
Webster AC, Wu S, Tallapragada K et al. Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients. Cochrane Database Syst Rev. 2017; 7 (7): CD004756.
Sethi S, Jordan SC. Novel therapies for treatment of antibody-mediated rejection of the kidney. Curr Opin Organ Transplant. 2023; 28 (1): 29-35.
Tasaki M, Saito K, Nakagawa Y et al. Bortezomib eliminates plasma cells from a renal graft in plasma cell-rich acute rejection. Transplant Proc. 2019; 51 (6): 1732-1738.
Eskandary F, Regele H, Baumann L et al. A randomized trial of bortezomib in late antibody-mediated kidney transplant rejection. J Am Soc Nephrol. 2018; 29: 591-605.
Suchanek O, Clatworthy MR. Novel strategies to target the humoral alloimmune response. HLA. 2020; 96 (6): 667-680.
Gabardi S, Martin ST, Roberts KL, Grafals M. Induction immunosuppressive therapies in renal transplantation. Am J Health Syst Pharm. 2011; 68 (3): 211-218.
Kumar D, Yakubu I, Safavi F et al. Lack of histological and molecular signature response to tocilizumab in kidney transplants with chronic active antibody mediated rejection: a case series. Kidney360. 2020; 1: 663-670.
Massat M, Congy-Jolivet N, Hebral AL et al. Do anti-IL-6R blockers have a beneficial effect in the treatment of antibody-mediated rejection resistant to standard therapy after kidney transplantation? Am J Transplant. 2021; 21: 1641-1649.
Ruangkanchanasetr P, Satirapoj B, Termmathurapoj S et al. Intensive plasmapheresis and intravenous immunoglobulin for treatment of antibody-mediated rejection after kidney transplant. Exp Clin Transplant. 2014; 12 (4): 328-333.
Larpparisuth N, Vongwiwatana A, Vareesangthip K, Cheunsuchon B, Parichatikanon P, Premasathian N. Clinicopathologic features and treatment response of early acute antibody-mediated rejection in Thai kidney transplant recipients: a single-center experience. Transplant Proc. 2014; 46 (2): 474-476.
Full text
10.35366/116363